TB-500 (Thymosin Beta-4 Fragment): What the Evidence Actually Shows

TB-500 is a lab-made peptide (a short chain of amino acids, the building blocks of proteins) that’s sold widely as a “healing” and recovery product. It’s important to keep it separate from the natural protein it’s copied from, because a lot of the upbeat marketing borrows trust from research that never actually used TB-500.

What it is

Thymosin beta-4 (Tβ4) is a protein your body makes naturally. It’s about 43-44 amino acids long, and it helps manage actin (a protein that forms part of a cell’s internal scaffolding). It has a hand in how cells move, how wounds heal, and how the body handles inflammation. TB-500 is not the full Tβ4 protein. It’s a short, lab-built piece based on the protein’s actin-binding region, and it’s sold almost entirely through research-chemical sellers rather than pharmacies.

The claims

Sellers and online forums promote TB-500 for faster healing of muscle, tendon, and ligament injuries, less inflammation, better flexibility, hair growth, and general recovery. These claims usually go along with injecting it, either subcutaneously (under the skin) or intramuscularly (into a muscle).

What the evidence actually shows

This is where the biggest gap shows up. The healing claims lean mainly on animal and cell studies of thymosin beta-4 — and those studies do show real effects on wound repair, corneal (eye-surface) healing, and tissue regrowth in rodents and lab models.

Human trials do exist, but they tested the full-length Tβ4 molecule, not the TB-500 fragment — and mostly for problems that have nothing to do with athletic recovery. A company called RegeneRx developed Tβ4-based products, including an eye drop (RGN-259) for dry eye and neurotrophic keratopathy (an eye-surface disease) and an injectable (RGN-352) aimed at heart and other tissue injury. The eye-drop program has reported reaching late-stage (phase 3) trials for neurotrophic keratopathy, but results across the wider program have been mixed, and none has reached FDA approval. A first-in-human phase I study in China tested recombinant Tβ4 (44 amino acids) given intravenously (into a vein) in healthy volunteers and found it was well tolerated — but that study was just checking safety and finding a workable dose, not proving the drug works.

Here’s the key point: no completed phase 2 or phase 3 randomized controlled trial (a carefully designed human study, the gold standard for testing whether something works) has tested injectable TB-500 (or Tβ4) for tendon, ligament, or muscle injury in people. So the very thing most buyers want it for has essentially no direct human evidence that it works.

Legal and regulatory status

TB-500 isn’t approved by the FDA for any human use. Its compounding status (whether a pharmacy is allowed to mix it up to order) is unsettled and keeps shifting. The FDA had put thymosin beta-4 in Category 2 of its interim list for 503A pharmacy compounding — the bucket for substances that may carry serious safety risks, which in practice blocked compounding. The agency pointed to worries like immunogenicity (the risk of triggering an unwanted immune reaction), impurities, and thin human safety data. Then in April 2026, the FDA took thymosin beta-4 (along with several other peptides) off Category 2 after the nominations were withdrawn, and scheduled it for review by the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026. Coming off Category 2 does not mean it’s approved or free to compound: thymosin beta-4 has never been on Category 1 (the list of substances cleared for compounding), so its status stays up in the air until that review and any rules that follow. Products sold online are labeled “research use only” and aren’t quality-checked the way real medicines are.

In sports, TB-500 is banned. WADA and USADA (the world and U.S. anti-doping agencies) prohibit thymosin beta-4 and its derivatives at all times — both in and out of competition — under Section S2 (peptide hormones, growth factors, and related substances). It’s been banned since the 2012 Prohibited List took effect, and athletes have been penalized for using it.

Safety

The honest answer: nobody has really studied how safe the TB-500 fragment is in humans. Full-length Tβ4 was generally well tolerated in small early trials, but that doesn’t automatically carry over to a different molecule made by unregulated sellers. When independent labs test research-chemical peptides, they keep finding products with the wrong contents, impurities, and contamination — and that adds risk on top of the peptide itself. One concern people often raise, at least in theory, is that a compound that encourages tissue growth and new blood-vessel formation might also feed tumor growth; that question hasn’t been settled in humans. None of this is medical advice.

Bottom line

TB-500’s reputation rests on animal data for a related-but-different molecule, plus a few human trials of full-length Tβ4 that never tested the fragment for the uses it’s actually sold for. It’s unapproved, not currently allowed for compounding, banned in sport, and sold through unregulated channels. Treat the bold healing claims as unproven.

Evidence grade: 4/10 · Animal-leaning.

Sources

• A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers (PMC)
• Progress on the Function and Application of Thymosin β4 (review, Frontiers in Endocrinology)
• FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (FDA Law Blog, April 2026)
• USADA — 2018 Prohibited List: Summary of Major Changes
• TB-500 — Status, Risks, and Bans in Sport and Military (BSCG)
• FDA, Bulk Drug Substances Used in Compounding Under Section 503A (interim list / Category 2 designations)
• RegeneRx Biopharmaceuticals — Tβ4-based clinical programs (RGN-259 ophthalmic; RGN-352 injectable)